Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL

Blood Adv. 2023 Oct 24;7(20):6156-6162. doi: 10.1182/bloodadvances.2023010673.

John R Davies¹, Laura K Hilton^{2

3}, Aixiang Jiang², Sharon Barrans⁴, Catherine Burton⁴, Peter W M Johnson⁵, Andrew J Davies⁵, Ming-Qing Du⁶, Reuben Tooze⁷, Francesco Cucco^{6

8}, Matthew A Care⁷, Ryan D Morin^{2

3

9}, Christian Steidl^{2

10}, Chulin Sha¹¹, David R Westhead¹, David W Scott^{2

12}

¹ School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.
² BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada.
³ Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
⁴ Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals, Leeds, United Kingdom.
⁵ School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
⁶ Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
⁷ Section of Experimental Haematology, University of Leeds, Leeds, United Kingdom.
⁸ Institute of Clinical Physiology (IFC), Consiglio Nazionale delle Ricerche, Pisa, Italy.
⁹ Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, BC, Canada.
¹⁰ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
¹¹ Institute of Basic Medicine and Cancer, Chinese Academy of Science, Hangzhou, China.
¹² Division of Medical Oncology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

No abstract available

MeSH terms